1. Home
  2. |Insights
  3. |IG Report Whacks DCMA's Oversight of Contractors' Business Systems

IG Report Whacks DCMA's Oversight of Contractors' Business Systems

Client Alert | less than 1 min read | 10.13.15

On October 1, the DoD IG released a report entitled, "Evaluation of Defense Contract Management Agency Actions on Reported DoD Contractor Business System Deficiencies," asserting that DCMA contracting officers "repeatedly" failed to comply with DFARS requirements involving reported business system deficiencies. The report, which is similar to one issued on June 29 regarding DCMA's treatment of estimating system deficiencies (available here), focused its criticisms on DCMA, despite DCMA's comments noting that DCAA, rather than DCMA, is responsible for determining whether a "significant" business system deficiency exists.

 

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights